Acrylamide

Acrylamide

SCHEMBL5499336

C=CC(=O)N1CCOC1=O.C=CC(N)=O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
FGFR4 P22455 1/20 0.39
NAAA Q02083 10/20 0.38
FAAH O00519 6/20 0.35
BTK Q06187 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354728 0.93 NAAA (0.42) NAAAFAAH
SCHEMBL3145817 0.74
SCHEMBL4806247 0.70 NAAA (0.44) NAAAFAAH
SCHEMBL4806256 0.70 NAAA (0.44) NAAAFAAH
SCHEMBL7569177 0.69 NAAA (0.48) NAAAFAAH
Acrylamide SCHEMBL8498177 0.69 ALDH1A1 (0.58) ALDH1A1TSHRFGFR4BTK
Acrylamide SCHEMBL3714624 0.69 ALDH1A1 (0.58) ALDH1A1TSHRFGFR4BTK
SCHEMBL18402201 0.69 NAAA (0.39) NAAAFAAH
SCHEMBL8194221 0.69 NAAA (0.50) NAAAFAAH
SCHEMBL21641600 0.69 POLB (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262299-B2 Diels-Alder reaction; using zeolite y in exchanged with copper; separated from mixture for reuse JOHNSON MATTHEY PLC (GB) 2007-08-28 US disclosed
US-20050033100-A1 Catalysts JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033100-A1 Catalysts DERA, AGL, INF2 ALDH1A1 1077/4885TSHR 2840/4885FGFR4 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.